All In Biotech

Drug Trial Radar · NCT05171673

Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury

A Multi-center, Prospective, Open-label, Controlled Study of the Pharmacokinetics and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injuries

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

151

Actual

Start

Oct 31, 2021

Primary completion

Jun 30, 2024

Study completion Jul 12, 2024

Sponsor

Lead sponsor
IBSA Institut Biochimique SAIndustry
Sponsor type
Industry
First posted
Dec 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries. 150 male and female participants aged 6-16 and 18-45 with soft tissue injuries meeting the following criteria will be enrolled to evaluate the pharmacokinetics and safety of the Licart topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. The analgesic effects will also be evaluated of the topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. To collect principal investigator-reported global response to therapy.

Conditions

  • Soft Tissue Injuries

Interventions

  • Licart™ (diclofenac epolamine) topical systemDrug

    The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Diclofenac Concentration of Licart™ Topical System at V2 and V5/EOS.Time frame: 24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
  2. Local Tolerability of the Licart™ Topical System as Assessed by a 7-point Scale.Time frame: 24 hours post-application (day 2 - V2), Day 4 (V3), Day 7 (V4), and Day 14 (V5) or EOS (the day after pain resolution)
  3. Number of Participants With Adverse Events as Assessed by the Study TeamTime frame: 14 days after participant received first dose
  4. Pharmacokinetics of the Licart™ Topical System as Assessed by the Activated Partial Thromboplastin Time (aPTT)Time frame: 24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Applied Research Center

    Little Rock, Arkansas

  • Atella Clinical Research, LLC.

    La Palma, California

  • University Clinical Research - Deland, LLC

    DeLand, Florida

  • My Community Research, Inc.

    Miami, Florida

  • D & H Tamarac Research Centers, Inc.

    Tamarac, Florida

  • Research Integrity

    Owensboro, Kentucky

  • Ascendant Research Clinic, LLC.

    Alamogordo, New Mexico

  • Prime Global Research Inc.

    The Bronx, New York

  • Ascendant Research Clinic, LLC.

    Marion, South Carolina

  • Next Level Urgent Care

    Houston, Texas

  • AIM Trials

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.